2024年第5版《NCCN肿瘤临床实践指南:非小细胞肺癌》更新解读

Interpretation of the updated NCCN clinical practice guidelines in oncology:Non-small cell lung cancer(version 5.2024)

肺癌是全球癌症相关死亡的主要原因,尤其是非小细胞肺癌(non-small cell lung cancer,NSCLC)。随着低剂量螺旋CT普及和人们体检意识提高,肺结节检出人数增多,对规范化的诊疗指南需求更大。2024年4月23日,美国国家综合癌症网络发布第5版NSCLC临床实践指南。与2023年第5版指南相比,2024年第5版更新内容主要集中于诊断评估、围手术期全身治疗、晚期NSCLC治疗和分子标志物检测等方面。本文将对其进行解读,旨在为我国的肺癌诊治提供最新指导方案及参考。

Lung cancer is the leading cause of cancer-related deaths worldwide,especially non-small cell lung cancer(NSCLC).With the popularization of low-dose CT and the improvement of people's awareness of physical examinations,the number of detected pulmonary nodules is gradually increasing,and there is a greater demand for standardized diagnostic and treatment guidelines.On April 23,2024,the National Comprehensive Cancer Network updated its clinical practice guidelines for NSCLC to the version 5.Compared with the version 5 in 2023,the version 5 in2024 updates focus on diagnostic evaluation,perioperative systemic therapy,treatment of advanced NSCLC,and molecular marker testing,which will be interpreted in this article with the aim of providing the latest guidance and reference for the diagnosis and treatment of lung cancer in China.